25
Jul
2024

PBMs Feel the Heat, Megarounds Abound, and the XBI Tops 100

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more.

 
 

You may also like

Nobel for Protein Design and AlphaFold, Scholar Rock Shines, and a City is Born
BioAge Goes Public, Kailera Piles into GLP-1, and Lilly Bets Big on Indiana
Pfizer Withdraws Sickle Cell Drug, Arch Hauls in $3B, and BMS Wins Schizophrenia OK
Recursion Scoops up Rival, Servier’s Brain Cancer Win, & Cell Therapy for Solid Tumors